Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EMRIS Pharma
Jerusalem, Israelemris-pharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
EMRIS Pharma is developing a novel small molecule-based topical drug aimed at preventing or treating skin toxicities—primarily papulopustular rash—caused by EGFR inhibitors used in cancer therapy. The approach is based on over a decade of research by leading Israeli scientists. The company’s lead program targets a significant unmet need, as up to 90% of patients treated with EGFR-targeted monoclonal antibodies experience these rashes, which can impact both quality of life and adherence to cancer treatment regimens. No clinical results have been published yet.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small molecules (topical administration)
- Industry
- Biotech
02
Partnerships
Hadasit (Hadassah Medical Center’s technology transfer arm)Yissum (Hebrew University’s technology transfer arm)NGT Healthcare2 VC [as investor/supporter rather than commercial partner so far].
Beyond the preview
Go deeper on EMRIS Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMRIS Pharma.